Spotlight: GPCR Assay Technologies
23 April 2026GPCR Assay Technology Spotlights
G protein-coupled receptors (GPCRs) play a crucial role in many aspects of our biology, justifying their position as the most targeted family of cell surface receptors in drug discovery.
One key property of GPCRs is their ability to activate multiple downstream signalling pathways, from G protein activation and β-arrestin recruitment, to second messengers like cAMP, and gene transcription.
As the discovery landscape shifts toward more complex pharmacology such as biased signalling, allosteric modulation, and kinetic profiling, it is essential to have a reliable set of assay platforms that deliver sensitivity, robustness, and biologically relevant readouts (and a team of experts to decode them!).
This presents a choice of assay possibilities for the budding discovery team interested in GPCR drug discovery. Which pathway is most relevant to the disease model? How can one exploit GPCR signalling pathways to drive success in early-stage discovery?
β-Arrestin and G protein Functional Assays. Detection of (A) β-arrestin recruitment and (B) Gs activation upon agonist stimulation of a class B GPCR. (C) Antagonist IC50 characterisation through inhibition of Gs activation. (D) Agonist driven β-arrestin mediated internalisation of a target GPCR.
G Protein and β‑Arrestin Recruitment Assays: Illuminating Pathway Selectivity
Modern GPCR discovery programmes increasingly require more than simple concentration-response to a single downstream response, instead requiring a complete picture of the various GPCR-mediated responses involved. Pathway bias / functional selectivity, allosteric modulation and spatiotemporal targeting require a broad characterisation of lead compound mechanism-of-action. Recruitment and activation assays, using technologies such as enzymatic complementation, bioluminescence resonance energy transfer (BRET), or fluorescent biosensors, allow us to quantify signalling across multiple downstream pathways.
Benefits include:
- Direct measurement of G protein activation (Gαs, Gαi/o, Gαq/11, G12/13 and isoform specific) or β‑arrestin recruitment, supporting a complete signalling profile.
- Endpoint formats suitable for high-throughput screens and exploring SAR.
- Kinetic modes that reveal ligand-dependent differences in signalling kinetics, biased signalling, and receptor trafficking.
These assays have become essential for projects exploring more complex pharmacological mechanism where traditional readouts fall short.
Summary of GPCR Signalling Pathways. Figure adapted from BioRender.
Second Messenger Assays
GPCR secondary messenger screening can be a powerful tool across hit identification and lead optimisation programmes. Exploitation of signal amplification and receptor overexpression can allow early detection of low efficacy hits, while kinetic analysis of downstream messengers provide fundamental insights into emerging leads for future clinical testing.
Endpoint Secondary Messenger Assays: A Proven Standard for High-Throughput GPCR Screening
Assays technologies based on the detection of target second messengers (e.g., cAMP, IP-one, pERK) by specific antibodies such as Alpha Assays or HTRF technology (supplied by Revvity), offer unmatched reliability from a well-validated platform that delivers consistent data at scale.
Key benefits:
- High sensitivity and low background noise makes these ideal for early-stage high-throughput screening campaigns.
- Robust, homogeneous protocols reduce assay variability and are fully automation friendly.
- Excellent dynamic range supports confident lead ranking and SAR decision making.
HTRF Functional screening assays. Use of HTRF detection assays to quantify (A) Gs-coupled GPCR mediated accumulation of cAMP upon agonist addition; (B) Gi-coupled GPCR mediated depletion of forskolin stimulated-cAMP production upon agonist addition and (C) Gq-coupled GPCR mediated accumulation of IP1 upon agonist addition (D) Gs-coupled GPCR mediated accumulation of cAMP in response to agonist with and without positive allosteric modulator (PAM) co-addition.
Live-cell Secondary Messenger detection assay. Detection of cAMP accumulation upon agonist action at a Gs-coupled GPCR in both Endpoint (A) and Kinetic (B) assay modes using cADDis biosensor (Montana Molecular).
Biosensor Assays: Real-Time Insight into GPCR Signalling
Genetically encoded biosensors bring live cell kinetic measurement of secondary messenger signalling into routine workflows. For campaigns requiring temporal insight or mechanism of action differentiation, biosensor assays deliver information that endpoint assays simply cannot match.
Key benefits:
- True kinetic resolution - capture signalling onset, peak, and decay, not just an endpoint snapshot.
- Non-destructive, live-cell readout enables repeated measurements and richer pharmacology.
- Ideal for assessment of ligand bias, PDE inhibitor profiling, and complex signalling dynamics of GPCRs (e.g. intracellular signalling).
For teams seeking to strengthen GPCR discovery programmes, explore our Excellerate Targets Capabilities pages, or Contact Us here.
Additionally, see examples of Excellerate GPCR expertise in action in our Publication History.
